Daewoong's SGLT-2 Inhibitor Set For First Filing After Phase III
First Korean Contender In Class
Korean pharma firm poised to file for domestic approval of SGLT-2 inhibitor enavogliflozin after positive top-line Phase III data, marking progress for the country's first drug in the already crowded class. But will it be competitive?
